In humans, IGF-I and -II have an important role in pre-and postnatal growth. The IGFs circulate in plasma principally as a ternary complex with the IGF binding protein-3 and an acid-labile subunit (ALS), which increases their half life.
F
etal growth is under the control of genetic, environmental, and nutritional factors. Infants born small for gestational age (SGA) may experience metabolic derangements during intrauterine life, which may predispose them to increased fetal and neonatal mortality and morbidity (1) and an increased risk of disorders in adult life, such as cardiovascular disease, diabetes, and obesity (2) .
Fetal growth restriction may be the consequence of maternal, fetal, or placental factors. The IGFs appear to be major determinants of fetal growth (3) and are expressed in the mother, fetus, and placenta in most species (4) . We recently showed that IGF-I and IGF-I receptor mRNA and protein are higher in placentas from SGA compared with appropriate for gestational age (AGA) placentas (5) .
In postnatal human serum, most IGFs circulate as 150-kDa ternary complexes consisting of one molecule of IGF-I or IGF-II, IGF binding protein (IGFBP)-3, the predominant form in serum, and a 84-to 86-kDa glycoprotein, the acid-labile subunit (ALS). ALS is mainly produced by the liver and is encoded by the IGFALS gene (16p13.3) (6). The ternary complex serves to stabilize the IGFs by extending their half-life from 10 min in the free form to more than 12 h in the complex (7) . Recently several ALS mutations have been reported in patients presenting with impaired postnatal growth, but it is uncertain whether prenatal growth is affected by an IGFALS gene defect because limited data on birth weight have been reported in these patients (8) .
To the best of our knowledge, no data on placental ALS gene expression and/or protein content have been published so far. Therefore, the aim of our study was to evaluate whether the human placenta expresses the ALS gene and its protein and to investigate any possible differences in these parameters in placentas from SGA and AGA newborns.
Subjects and Methods

Sample collection
We collected placentas from 47 AGA [birth weight ϭ 0.11 Ϯ 0.11 SD score (SDS)] and 42 idiopathic SGA newborns (birth weight ϭ Ϫ2.11 Ϯ 0.10 SDS) from full-term pregnancies (37-40 wk of gestation) as previously described (6) . All mothers gave their informed consent, and the protocol was approved by the Institutional Review Board of the San Borja Arriará n Clinical Hospital in Santiago, Chile.
Placental samples were rapidly processed as described by Wyatt et al. (9) . The tissue was divided to obtain placental samples from the chorionic (CPs) and basal plates (BPs). The cord blood was centrifuged and the serum was aliquoted and stored at Ϫ20 C until assayed.
RNA preparation, cDNA synthesis, and RT-PCR
Total RNA was isolated from the frozen placentas (CPs and BPs) and cDNA was synthesized as previously described (5) (see Supplemental Materials and Methods, published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org).
Gene amplifications
The IGFBP3 (224 bp, gene ID 3486) upstream 5Ј-CTCCA-CATTCAGAGGCATCA-3Ј and downstream 5Ј-AGCCATTC-CTCCTTCCTGTT-3Ј; ALS (238 bp, gene ID 3438) upstream 5Ј-GTGCTCACGCTAGACCACAA-3Ј and downstream 5Ј-CCGTTGTCCTTGAGGAAGAG-3Ј. For IGF, IGF2, and 18S rRNA, we used the primers previously described (5). The RT-PCR was developed as described in Supplemental Materials and Methods. Semiquantification of PCR products was performed by image analysis (Kodak 1D image analysis software; Rochester, NY). The amplified product identity of the ALS gene was confirmed by sequencing in purified PCR products (Macrogen Inc., Seoul, Republic of Korea).
Assays
Total IGF-I and IGF-II serum concentrations and placental contents were determined in homogenates from frozen placentas as previously described (5) .
IGFBP-3 concentrations were measured by IRMA (Diagnostic System Laboratories Inc., Webster, TX). The sensitivity of the method was 100 ng/ml for cord serum samples and 10 ng/ml for placental homogenates. The intra-and interassay coefficients of variation were 1.1 and 1.8%, respectively. ALS concentrations were measured by RIA (Bioclone, Sydney, New South Wales, Australia). The sensitivity of the method for serum and homogenates samples was 0.02 nmol/liter. The intra-and interassay coefficients of variation were 4.5 and 5.1%, respectively.
Immunohistochemistry
Immunohistochemical staining for ALS was performed on 5-to 6-m formalin-fixed, paraffin-embedded placental sections using immunoperoxidase method using an anti-ALS host goat (Santa Cruz Biotechnology, Santa Cruz, CA) (see Supplemental Materials and Methods).
Western blot analysis
Equal amounts (25 g) of different tissue proteins were resolved using 10% SDS-PAGE and subsequently transferred to nitrocellulose membranes. The membranes were blocked and then probed with an antibody against ALS (see Supplemental Material and Methods).
Statistical analysis
Results are shown as mean Ϯ SEM. Differences were assessed by t test or Mann Whitney U test. To compare the results of the BP and CP in each placenta, we used the paired t test or Wilcoxon test. The studies of correlations were performed using the Pearson or Spearman tests. Statistics were performed using SPSS version 11.5, and a value of P Ͻ 0.05 was considered significant.
Results
The clinical and hormonal data of the newborns are shown in Supplemental Table 1 . As expected, the SGA newborns had significantly lower birth weight SDS, birth length SDS, head circumference SDS, and placental weight than the AGA newborns. In addition, mean IGF-I, IGF-II, IGFBP-3, and ALS cord blood levels were significantly lower in SGA compared with AGA newborns.
Placental messenger of ALS mRNA
ALS mRNA amplification produced a single band of 208 bp (Fig. 1A) . Semiquantitative RT-PCR showed that ALS is present in human placenta in both the CPs and BPs. The amplified product identity of the ALS gene was confirmed by sequencing in purified PCR products; the homology was 100% with human ALS in four samples analyzed.
Placental mRNA level according birth weight
ALS mRNA level (Fig. 1B ) was higher in both the CP and BP from the SGA placentas compared with the AGA placentas. As we previously reported, the mRNA expression of IGF-I was higher in the CP and BP from SGA placentas compared with the same plates from AGA placentas (5) (Supplemental Table 1 ). The IGFBP3 mRNA was slightly higher in the CPs and BPs of the SGA placentas compared with the AGA placentas, but this difference did not reach statistical significance (Supplemental Table 1 ).
Placental protein content
We detected the ALS protein in human placentas by immunohistochemistry and Western blot (95 kDa, Fig.  2A ). Positive immunostaining for ALS was observed in the cytoplasm of the cytotrophoblast and in the syncytiotrophoblast from the BPs (Fig. 2B, BP) , and CPs (Fig. 2B, CP) of the placentas. No staining for ALS was observed in endothelial or mesenchymal cells from the placental villi.
The ALS protein content was higher in the CPs of the SGA compared with the AGA placentas. No differences were observed in the BP of the placentas between the SGA and AGA groups (Fig. 2C) .
The IGF-I protein content was higher in the CP of the SGA placentas compared with the AGA placentas (89.3 Ϯ 6.2 vs. 75.4 Ϯ 4.7 ng/g placenta, respectively, P Ͻ 0.05). Similarly, the placental IGF-II protein content in the CP of the SGA placentas was higher compared with the AGA placentas (396 Ϯ 21 vs. 326 Ϯ 19 ng/g placenta, respectively, P Ͻ 0.05). Moreover, we observed a higher IG-FBP-3 protein content in the CP compared with the BP from SGA placentas (704 Ϯ 42 vs. 546 Ϯ 35 ng/g placenta, respectively, P Ͻ 0.05).
We observed an inverse correlation between birth weight with ALS mRNA and protein content in the CP of the placentas and directly with cord blood concentration (r ϭ Ϫ0.385, r ϭ Ϫ0.237, r ϭ 0.386, respectively, P Ͻ 0.05).
Discussion
The placenta is an important organ for the supply of maternal substrates to the fetus. Fetal growth is a complex process regulated by various maternal, placental, and fetal factors. We have studied the ALS, an important component of the ternary complex of the IGF system.
Our study shows that the ALS is expressed in the human placenta. In addition, we show that placental ALS mRNA level was higher in the SGA compared with AGA placentas, particularly in their CP. In addition, we observed a significant increase in ALS protein content in the CP of the SGA compared with AGA placentas, suggesting that ALS may play a possible role in fetal growth. To our knowledge, this is the first study that describes ALS mRNA expression and protein content in human placentas according to birth weight. The IGF-I and -II play crucial roles in growth and development. IGF-I is synthesized by a variety of cell types and is involved in linear growth, cell proliferation, and differentiation. Most of these effects are mediated by both endocrine and autocrine/paracrine mechanisms through the IGF-I receptor (10) . In circulation, almost all the IGFs are present as 150-kDa ternary complexes comprised of one molecule of IGF, IGFBP-3, and an 85-kDa glycoprotein, the ALS (11). This ternary complex prolongs the halflife of the IGFs and allows them to remain in circulation, which facilitates their endocrine action. ALS is mostly produced by the liver, although ALS gene expression has been detected in some extrahepatic tissues, such as the kidney, bone, mammary gland, thymus, and lung (7) . In humans, ALS is undetectable in fetal serum at 27 wk of gestation but is present at term (12) . Proteolysis of IGFBP-3 and interactions of the ternary complex with proteoglycans have been shown to release IGFs (7). It is also possible that much of the released IGFs are the product of the equilibrium between the ternary complex and its individual components.
Inactivation of the IGFALS gene in mice produced a modestly growth deficient (13-20% smaller at 10 wk), despite a 62 and 88% reduction in IGF-I and IGFBP-3 plasma levels, respectively (8) . It is uncertain whether prenatal growth in humans is affected by an IGFALS gene defect. However, some degree of postnatal growth restriction has been reported in patients with mutations of the IGFALS gene (8) .
There are limited data on placental IGFBP-3 expression in humans. In our study, the IGFBP-3 mRNA level was similar in SGA and AGA placentas, as previously reported in sheep (13) . However, in placentas from preeclamptic pregnancies between 35 and 40 wk of gestation, a lower expression of IGFBP-3 compared with normal pregnancies has been reported (14) . In addition, we documented higher IGFBP-3 protein content in the CP compared with the BP from the SGA placentas, suggesting a gradient for IGF-I, IGFBP-3, and ALS concentrations in the placenta.
As we previously reported (5), we also found a higher expression of IGF-I mRNA and protein content in SGA compared with AGA placentas. We have measured IGFBP-1 and IGFBP-2 in placental tissues, and we have observed that their placental concentrations are lower or similar to those observed in cord blood and in serum from prepubertal children (see Supplemental Table 2) . Therefore, the possible interference by IGFBPs in our IGF-I assay is likely to be relatively minor.
The higher ALS, IGF-I, and IGFBP-3 mRNA expression and protein content in SGA compared with AGA placentas suggests a possible role for these important components of the ternary complex in fetuses with growth restriction.
In conclusion, we have described for the first time the ALS mRNA and protein expression in human placentas, and we have shown increased mRNA and protein contents for IGF-I, IGFBP-3, and ALS in full-term placentas from SGA compared with AGA newborns. Our results suggest that the increase in IGF-I, IGFBP-3, and ALS mRNA expression and protein content observed in SGA compared with AGA placentas may represent a placental compensatory mechanism in response to fetal growth restriction.
